...
首页> 外文期刊>Journal of cancer survivorship: research and practice >Evaluating long-term patient-centered outcomes following prostate cancer treatment: Findings from the Michigan Prostate Cancer Survivor study
【24h】

Evaluating long-term patient-centered outcomes following prostate cancer treatment: Findings from the Michigan Prostate Cancer Survivor study

机译:评估前列腺癌治疗后以患者为中心的长期结果:密歇根州前列腺癌幸存者研究的发现

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Context: Advances in screening and treatment of prostate cancer have dramatically increased the number of survivors in the US population. Yet the effect of screening is controversial, and in some instances may not be beneficial. Previous studies have typically only reported outcomes of treatment and symptoms within a short time frame following treatment. The persistence of such symptoms over time necessitates an improvement of survivor care so that the medical and support needs of these patients are met. Objective: This study aims to perform a patient-centered survey of prostate cancer survivors in the Michigan Cancer Registry to identify treatment side effect rates, evaluate survivors' access to preventive care services post-prostate cancer treatment, and assess the informational needs of these survivors regarding their prostate cancer. Design, setting, and patients: Linking case files of the Michigan Cancer Registry with records from the National Death Index, we identified prostate cancer patients diagnosed between 1985 and 2004 and alive on 31 December 2005. Participants were selected using a stratified cross-sectional sampling strategy to ensure adequate inclusion of survivors based upon race and ethnicity, urban versus rural location, and number of years since diagnosis of prostate cancer. A total of 2,499 surveys were completed and returned. Main outcome measures: (1) Physical symptoms-assessing bowel, sexual, urinary, and vitality symptoms by treatment modality. (2) Access to care-identifying whether diagnostic tests for prostate cancer (prostate-specific antigen (PSA) and digital rectal examination) were performed. Determining whether the survivors had knowledge of the "watchful waiting" paradigm for prostate cancer surveillance. (3) Informational needs-assessing whether the informational needs of patients were addressed by providers. Evaluating the significant predictors associated with seeking information about prostate cancer from any other source. Identifying what factors influenced a person to actively seek out information and what factors guide which primary information source a survivor would use. Results: Median duration between prostate cancer diagnosis and survey response was 9 years. Of the study population, 80 % was diagnosed at an early stage. Survivors had reported significant problems in the 4 weeks prior to survey. Of the survivors, 88.1 % reported having a PSA test since diagnosis of prostate cancer, with 93 % of them having it done at least once per year. Of the survivors, 82.6 % reported that a healthcare provider gave them information on prostate cancer. Of this 82.6 %, 86.4 % had this information provided by a urologist, 45.4 % by a primary care physician, and 29.2 % by an oncologist. The primary source of information for these survivors was "healthcare provider" (59.2 %). Conclusion: Persistent symptoms subsequent to prostate cancer treatment suggest a gap in symptom management. Future research should support long-term studies of active surveillance versus active treatment outcomes to understand the feasibility of minimizing the burden of long-term physical symptoms arising from prostate cancer treatment. Clinicians must assess post-treatment distress long after treatment has ended to identify when supportive care is needed. More informational resources should be allocated to prostate cancer survivors to ensure that they are well-educated about their prognosis. Implications for Cancer Survivors: This study is needed to ensure that the post-treatment symptoms of prostate cancer survivors are properly addressed and managed by healthcare providers over the long term.
机译:背景:筛查和治疗前列腺癌的进展大大增加了美国人口中幸存者的数量。筛选的效果尚存争议,在某些情况下可能不是有益的。先前的研究通常仅报道治疗后短时间内的治疗结果和症状。随着时间的流逝,这些症状的持续存在需要改善幸存者的护理,以便满足这些患者的医疗和支持需求。目的:本研究旨在在密歇根州癌症登记处进行以患者为中心的前列腺癌幸存者调查,以确定治疗的副作用率,评估幸存者在前列腺癌治疗后获得预防保健服务的机会,并评估这些幸存者的信息需求关于他们的前列腺癌。设计,地点和患者:将密歇根州癌症登记处的案例文件与美国国家死亡指数的记录相链接,我们确定了1985年至2004年之间诊断并在2005年12月31日还活着的前列腺癌患者。使用分层的横断面抽样选择参与者。根据种族和种族,城市与乡村的位置以及自诊断前列腺癌以来的年限,确保幸存者得到充分纳入的策略。总共完成了2499次调查并返回。主要结果指标:(1)身体症状-通过治疗方式评估肠,性,尿和生命力症状。 (2)获得医疗服务,以识别是否进行了前列腺癌的诊断检查(前列腺特异性抗原(PSA)和直肠指检)。确定幸存者是否了解前列腺癌监视的“观察等待”范例。 (3)信息需求-评估提供者是否满足了患者的信息需求。评估与从任何其他来源寻求有关前列腺癌信息相关的重要预测因子。确定哪些因素会影响一个人积极地寻找信息,哪些因素将指导幸存者使用哪种主要信息来源。结果:前列腺癌诊断与调查反应之间的中位时间为9年。在研究人群中,80%在早期被诊断出。幸存者在调查前的4周内报告了严重问题。在幸存者中,有88.1%的人报告自诊断为前列腺癌以来接受了PSA测试,其中93%的人每年至少做过一次。在幸存者中,有82.6%的人报告说,医疗保健提供者向他们提供了有关前列腺癌的信息。在这82.6%的人中,有86.4%的信息是由泌尿科医师提供的,45.4%的是初级保健医师提供的,29.2%的是肿瘤科医生提供的。这些幸存者的主要信息来源是“医疗保健提供者”(59.2%)。结论:前列腺癌治疗后的持续症状提示症状管理方面存在差距。未来的研究应支持对主动监测与主动治疗结果进行长期研究,以了解最大程度减少前列腺癌治疗引起的长期身体症状负担的可行性。临床医生必须在治疗结束后很长时间评估治疗后的痛苦,以识别何时需要支持治疗。应该为前列腺癌幸存者分配更多的信息资源,以确保他们对预后有很好的认识。对癌症幸存者的影响:需要进行此项研究以确保长期护理前列腺癌幸存者的治疗后症状,并由医疗保健提供者正确解决和管理。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号